Chehregosha Fatemeh, Maghsoumi-Norouzabad Leila, Mobasseri Majid, Fakhr Laleh, Tarighat-Esfanjani Ali
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Nutrition Research Center, Department of Clinical Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
J Cardiovasc Thorac Res. 2024;16(3):184-193. doi: 10.34172/jcvtr.33231. Epub 2024 Sep 20.
This study aims to determine the effects of fenugreek seed dry extract (FDE) on the glycemic indices, lipid profile, and prooxidant-antioxidant balance (PAB) in patients with type 2 diabetes (T2D).
A double-blind randomized clinical trial was carried out on 54 individuals with T2D. Participants were randomly assigned to a FDE group (received 3 tablets containing 335 mg of FDE daily for 8 weeks) or a placebo group (received tablets containing microcrystalline cellulose). Anthropometric indices, physical activity, diet, fasting blood sugar (FBS), serum insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), triglyceride (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein (HDL-C), and PAB were assessed.
An eight-week intake of 3 tablets containing 335 mg of FDE decreased serum insulin (=0.016, <0.001), HOMA-IR (=0.009, <0.001), TG (<0.001, =0.001), and PAB (<0.001, <0.001) compared to the baseline, in both placebo and intervention groups respectively. TC decreased significantly compared to the baseline in the placebo group (=0.028), while HDL-C increased in the FDE group compared to the baseline (<0.001) and placebo group (=0.014).
In the present study even though changes of parameters were more in intervention group compared to the control group, we did not observe any significant differences between studied groups except for HDL-C. However, the effects might become apparent with a higher dosage, longer study duration, or a larger sample size compared to the placebo group. Further clinical trials are needed in this regard.
本研究旨在确定胡芦巴籽干提取物(FDE)对2型糖尿病(T2D)患者血糖指数、血脂谱和氧化还原平衡(PAB)的影响。
对54例T2D患者进行了一项双盲随机临床试验。参与者被随机分为FDE组(每天服用3片含335 mg FDE的片剂,持续8周)或安慰剂组(服用含微晶纤维素的片剂)。评估人体测量指标、身体活动、饮食、空腹血糖(FBS)、血清胰岛素、胰岛素抵抗稳态模型评估(HOMA-IR)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白(HDL-C)和PAB。
在安慰剂组和干预组中,与基线相比,连续8周每天服用3片含335 mg FDE的片剂分别降低了血清胰岛素(=0.016,<0.001)、HOMA-IR(=0.009,<0.001)、TG(<0.001,=0.001)和PAB(<0.001,<0.001)。与基线相比,安慰剂组的TC显著降低(=0.028),而与基线相比,FDE组的HDL-C升高(<0.001),且与安慰剂组相比也升高(=0.014)。
在本研究中,尽管干预组参数的变化比对照组更多,但除HDL-C外,我们未观察到研究组之间有任何显著差异。然而,与安慰剂组相比,更高的剂量、更长的研究持续时间或更大的样本量可能会使效果更加明显。在这方面需要进一步的临床试验。